The Claim
Elevated copeptin levels, as a marker of arginine vasopressin (AVP) activity, are independently associated with increased severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory subtype, metabolic dysfunction-associated steatohepatitis (MASH), in individuals with obesity.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese individuals, higher levels of copeptin, a marker of the hormone arginine vasopressin, are linked to more severe fat accumulation and inflammation in the liver.
See the scientific wording
Higher AVP levels, as indicated by copeptin, are independently associated with greater severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, MASH, in obese individuals, suggesting AVP signaling may drive liver fat accumulation and inflammation.
When the body is dehydrated or exposed to fructose, it releases more of a hormone called AVP. This hormone binds to receptors in the liver, making it produce more sugar and store more fat. It also tells fat cells to hold onto fat instead of releasing it, and blocks insulin from working properly. The extra sugar and fat in the liver cause inflammation and damage, leading to worse liver disease.
What the research says
1 studyThis study shows that when the body is dehydrated, a hormone called AVP goes up, and that might make fatty liver and liver inflammation worse—even if someone is just overweight. So higher AVP (shown by copeptin) seems to make liver disease worse, not just obesity.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.